Purpose: Mutations in the fibroblast growth factor receptor 3 (FGFR3) have been found in 70% of the low-grade non-muscle-invasive bladder cancer (NMI-BC) tumors. We aim to determine the potential of FGFR3 mutation analysis on voided urine to detect recurrences during surveillance of patients with low-grade NMI-BC. Experimental Design: FGFR3 mutation status of the study inclusion tumor was determined from 200 low-grade NMI-BC patients. Patients with an FGFR3-mutant inclusion tumor were selected for analysis and monitored by cystoscopy, and voided urine samples were collected. FGFR3 mutation analysis was done on 463 prospectively collected urines. Sensitivity and predictive value of the assay were determined for detection of concomitant recur...
Non-muscle invasive bladder cancers (NMI-BCs) represent 75% of bladder cancers upon presentation. Af...
BACKGROUND Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dise...
Most bladder cancer (BC) patients need life-long, invasive and expensive monitoring and treatment, m...
PURPOSE Mutations in the fibroblast growth factor receptor 3 (FGFR3) have been found in 70% of the l...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
textabstractThe identification of frequent FGFR3 mutations in superficial bladder cancer suggests ...
textabstractBackground: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die fr...
Background: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dis...
BACKGROUND: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dis...
BACKGROUND Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dise...
Non-muscle invasive bladder cancers (NMI-BCs) represent 75% of bladder cancers upon presentation. Af...
BACKGROUND Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dise...
Most bladder cancer (BC) patients need life-long, invasive and expensive monitoring and treatment, m...
PURPOSE Mutations in the fibroblast growth factor receptor 3 (FGFR3) have been found in 70% of the l...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
International audienceOBJECTIVE:To assess the diagnostic and prognostic performance of a noninvasive...
textabstractThe identification of frequent FGFR3 mutations in superficial bladder cancer suggests ...
textabstractBackground: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die fr...
Background: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dis...
BACKGROUND: Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dis...
BACKGROUND Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dise...
Non-muscle invasive bladder cancers (NMI-BCs) represent 75% of bladder cancers upon presentation. Af...
BACKGROUND Fifty percent of patients with muscle-invasive bladder cancer (MI-BC) die from their dise...
Most bladder cancer (BC) patients need life-long, invasive and expensive monitoring and treatment, m...